| Patents for A61P 37 - Drugs for immunological or allergic disorders (117,141) |
|---|
| 01/28/2010 | CA2731496A1 Pyrazolopyridine kinase inhibitors |
| 01/28/2010 | CA2731451A1 Pyrazolopyridine kinase inhibitors |
| 01/28/2010 | CA2731432A1 Tri-cyclic pyrazolopyridine kinase inhibitors |
| 01/28/2010 | CA2731356A1 Sulphone-substituted quinazoline derivatives as immuno-modulators, their preparation and use as medicaments |
| 01/28/2010 | CA2730500A1 Substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid deri vatives useful in the treatment of autoimmune and inflammatory disorders |
| 01/27/2010 | EP2147683A1 Construct and method for the internalization of cargo molecules into a cell |
| 01/27/2010 | EP2147676A1 Allergen inactivator |
| 01/27/2010 | EP2147672A1 Cytotoxic t cell activator comprising ep4 agonist |
| 01/27/2010 | EP2146974A1 N- hydroxy-4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4-yl)phenoxy]pentoxy} benzamidine 2 ethansulfonic acid salt, process for the preparation thereof and pharmaceutical composition comprising the same |
| 01/27/2010 | EP2146741A2 Medicaments and methods to treat autoimmune disease and cancer |
| 01/27/2010 | EP2146739A2 Methods of immune or hematological enhancement, inhibiting tumour formation or growth, and treating or preventing cancer, cancer symptoms, or the symptoms of cancer treatments |
| 01/27/2010 | EP2146703A1 Src family kinase inhibitors |
| 01/27/2010 | EP1924605B1 Compositions and methods for diagnosing and treating an inflammation |
| 01/27/2010 | EP1438298B1 Piperazine derivatives with ccr1 receptor antagonist activity |
| 01/27/2010 | EP1206563B1 Genetically altered dendritic cells transduced with adeno-associated virus (aav), methods of producing said cells and uses thereof |
| 01/27/2010 | CN101633907A Amplification culture method for antigen specific cytotoxic t lymphocytes |
| 01/27/2010 | CN101633689A Peptide selection method |
| 01/27/2010 | CN101632669A Method of using diketopiperazines and composition containing them |
| 01/27/2010 | CN101632663A Novel molecular target for neurotoxicity |
| 01/27/2010 | CN100584816C Kutkin derivative, preparation method and application thereof |
| 01/27/2010 | CN100584363C Traditional Chinese medicine oral liquid for treating damnification of immunity function after chemotherapy of cancer of the esophagus cancer patient |
| 01/27/2010 | CN100584362C Traditional Chinese medicine for treating leukocythemia |
| 01/27/2010 | CN100584343C Medicine health-care usage of globefish I collagen extraction and preparing process thereof |
| 01/27/2010 | CN100584342C Use of natural killer T cells in preparing immunological rejection medicine for cornea transplantation of mammal |
| 01/27/2010 | CN100584336C Medicinal compositions |
| 01/26/2010 | US7653495 Comprises series of steps including identifying cavity proximal to functional critical site, determining physical parameters of cavity, identifying functional groups which can be accommodated by cavity, testing compounds comprising such functional groups in an in vitro assay to determine which are active |
| 01/26/2010 | US7652144 Compounds as PDE IV and TNF inhibitors |
| 01/26/2010 | US7652141 Immunosuppressants, analgesics, antiinflammatory agents |
| 01/26/2010 | US7652060 Small molecule rotamase enzyme inhibitors |
| 01/26/2010 | US7652054 Gastrointestinal disorders; cardiovascular disorders; dyspepsia;anticancer agents; antiulcer agents |
| 01/26/2010 | US7652035 CRF receptor antagonists and methods relating thereto |
| 01/26/2010 | US7652022 N-(4-(4-(4-hydroxyphenylamino)-pyrimidin-6-yl)-oxyphenyl)-N'-(3-trifluoromethylphenyl)-urea; |
| 01/26/2010 | US7652012 2-(R)-(4-fluoro-2-methyl-phenyl)-4-(S)-((8aS)-6-oxo-hexahydro-pyrrolo[1,2-a]-pyrazin-2-yl)-piperidine-1-carboxylic acid [1-(R)-3,5-bis-trifluoromethyl-phenyl)-ethyl]-methylamide maleate and pharmaceutical compositions thereof |
| 01/26/2010 | US7651997 Deoxo-proline-containing tamandarin and didemnin analogs, dehydro-proline-containing tamandarin and didemnin analogs, and methods of making and using them |
| 01/26/2010 | US7651857 Inhibiting antigen presentation, comprising the step of supplying to an antigen-presenting cell, such as a dendritic cell, or precursor cell, a modulator, preferably an enhancer, of Toll-related receptor signalling |
| 01/26/2010 | CA2481012C Quinoline and isoquinoline derivatives, a process for their production and their use as inflammation inhibitors |
| 01/26/2010 | CA2471651C Amorphous substance of tricyclic triazolobenzazepine derivative |
| 01/26/2010 | CA2470064C Triazolo-quinolin derivatives useful as adenosine receptor ligands |
| 01/26/2010 | CA2465206C Polymeric thiol-linked prodrugs |
| 01/26/2010 | CA2447099C Delivery of compounds for the treatment of migraine through an inhalation route |
| 01/26/2010 | CA2421588C Tnf receptor-like molecules and uses thereof |
| 01/26/2010 | CA2349629C Methods for the production of tcr gamma delta t cells |
| 01/26/2010 | CA2338854C Nitric esters and nitrate salts of specific drugs |
| 01/26/2010 | CA2303934C Tetrazole-containing rapamycin analogs with shortened half-lives |
| 01/26/2010 | CA2301499C T-cell membrane protein (tirc7), peptides and antibodies derived therefrom and uses thereof |
| 01/26/2010 | CA2222524C Somatostatin peptides |
| 01/21/2010 | WO2010009380A2 Methods for treating immune-mediated dengue fever infections and antibody-dependent enhancement of dengue fever infections, including dengue hemorrhagic fever and dengue shock syndrome |
| 01/21/2010 | WO2010009129A2 Methods of treating autoimmune diseases using cd4 antibodies |
| 01/21/2010 | WO2010009091A2 Anti-inflammatory and anti-allergy extracts from nettle |
| 01/21/2010 | WO2010009069A1 Chromene modulators of chemokine receptor activity |
| 01/21/2010 | WO2010008843A1 Apoptosis signal-regulating kinase 1 inhibitors |
| 01/21/2010 | WO2010008005A1 Agent for ameliorating immune system function abnormality induced by stress |
| 01/21/2010 | WO2010008001A1 Aptamer against il-17 and use thereof |
| 01/21/2010 | WO2010007972A1 Novel indole derivative having carbamoyl group, ureide group and substituted oxy group |
| 01/21/2010 | WO2010007756A1 Pyridine derivative having ttk inhibition activity |
| 01/21/2010 | WO2010007316A2 Novel triazolo(4,3-a)pyridine derivatives, process for the preparation thereof, use thereof as medicaments, pharmaceutical compositions and novel use, in particular as met inhibitors |
| 01/21/2010 | WO2010007099A1 2-aminoimidazo[1,2-b]pyridazine derivatives as pi3k inhibitors |
| 01/21/2010 | WO2010007082A1 Compositions and methods of use for therapeutic antibodies |
| 01/21/2010 | WO2010006970A1 Novel phenylimidazopyrazines |
| 01/21/2010 | WO2010006939A1 Aminotetrahydroindazoloacetic acids |
| 01/21/2010 | WO2010006501A1 Annexin ii compositions for treating or monitoring inflammation or immune-mediated disorders field of the invention |
| 01/21/2010 | WO2010006447A1 Chimeric respiratory syncytial virus polypeptide antigens |
| 01/21/2010 | WO2009145989A3 Aminoalkylphenyl antagonists of prostaglandin d2 receptors |
| 01/21/2010 | WO2009137605A3 AFFINITY MATURED CRIg VARIANTS |
| 01/21/2010 | WO2009103319A3 Ezrin, serpin b5, peroxiredoxin-2 and heat shock protein beta-1 as autoantigens for treating or detecting streptococcal diseases |
| 01/21/2010 | WO2008156092A8 Azolylmethylidenehydrazine derivative and use thereof |
| 01/21/2010 | WO2008128045A8 Solid forms of (e) -1- (4- ( (1r, 2s, 3r) -1, 2, 3, 4-tetrahydroxybutyl) -1h-imidazol-2-yl)ethanone oxime |
| 01/21/2010 | WO2008116064A3 Fused heterocyclic compounds useful for the treatment of proliferative, allergic, autoimmune or inflammatory diseases |
| 01/21/2010 | WO2007041130A3 Deazapurines useful as inhibitors of janus kinases |
| 01/21/2010 | US20100016938 Diagnosing, monitoring and treating inflammation |
| 01/21/2010 | US20100016783 Non-invasive systems and methods for in-situ photobiomodulation |
| 01/21/2010 | US20100016557 HUMAN ANTIBODIES THAT BIND HUMAN TNFalpha |
| 01/21/2010 | US20100016391 Isoxazoline Compounds Having MIF Antagonist Activity |
| 01/21/2010 | US20100016386 Selective glycosidase inhibitors and uses thereof |
| 01/21/2010 | US20100016380 TNF-alpha production inhibitors |
| 01/21/2010 | US20100016357 Use of Beta-Aminoalcohols for the Treatment of Inflammatory Disorders and Pain |
| 01/21/2010 | US20100016348 Orally disintegrative dosage form |
| 01/21/2010 | US20100016302 7-tert-Butyl-3-(3-{8-[4-(morpholine-4-carbonyl)-phenylamino]-imidazo[1,2-a]pyrazin-6-yl}-phenyl)-3H-quinazolin-4-one; arthritis; inhibit Btk |
| 01/21/2010 | US20100016300 Imidazoacridine Compounds for Treating FLT3-Mediated Disorders |
| 01/21/2010 | US20100016289 Compounds Useful as Antagonists of CCR2 |
| 01/21/2010 | US20100016274 Beta-lactam cannabinoid receptor modulators |
| 01/21/2010 | US20100016250 Toll-like receptor 9 agonists |
| 01/21/2010 | US20100016233 Heterocyclic Aromatic Compounds Useful As Growth Hormone Secretagogues |
| 01/21/2010 | US20100016231 Treatment Of Rheumatoid Arthritis With Mammal Beta Defensins |
| 01/21/2010 | US20100016224 Compositions and methods for modulating an immune response |
| 01/21/2010 | US20100016216 Adiponectin and uses thereof |
| 01/21/2010 | US20100015593 Method for producing a composition for promoting survival of transplanted hematopoietic stem cell |
| 01/21/2010 | US20100015224 Programmable buoyant delivery technology |
| 01/21/2010 | US20100015214 Novel Trans-Adjuvant System |
| 01/21/2010 | US20100015211 Combination Approaches For Generating Immune Responses |
| 01/21/2010 | US20100015178 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase |
| 01/21/2010 | US20100015177 Method for Preserving Viral Particles |
| 01/21/2010 | US20100015173 Coiled-coil lipopeptide helical bundles and synthetic virus-like particles |
| 01/21/2010 | US20100015172 Method to reduce the physiologic effects of drugs on mammals |
| 01/21/2010 | US20100015171 Vaccines comprising tb 10.4 |
| 01/21/2010 | US20100015163 Dendritic cell potentiation |
| 01/21/2010 | US20100015162 treating interleukin-22 (IL-22)-associated disorder such as arthritis or psoriasis by administering the antibody in an amount sufficient to inhibit or reduce immune cell activity in the subject |
| 01/21/2010 | US20100015156 Diagnosis of inflammatory bowel disease in children |
| 01/21/2010 | US20100015145 Use of a compound for reducing the biological effectiveness of IL-6 |
| 01/21/2010 | US20100015130 Disc-1 pathway activators in the control of neurogenesis |